Related Experiment Video

Updated: Jul 19, 2026

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

Focal adhesion kinase: a potential target in cancer therapy

Maroesja J van Nimwegen1, Bob van de Water

  • 1Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Gorlaeus Laboratories, 2300 RA Leiden, The Netherlands.

Biochemical Pharmacology
|September 26, 2006
PubMed

Insights

Focal adhesion kinase (FAK) is crucial for cancer progression. Developing selective FAK inhibitors, potentially combined with cytotoxic agents, offers a promising anti-cancer therapy strategy.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in integrin and growth factor receptor signaling.
  • FAK regulates critical cellular processes including survival, proliferation, migration, and invasion, all implicated in cancer development and progression.
  • Overexpression and/or increased activity of FAK is frequently observed in various human cancers, suggesting its role in carcinogenesis.

Purpose of the Study:

  • To highlight the significant role of FAK in tumorigenesis, metastasis, and survival signaling.
  • To propose FAK as a potential therapeutic target for anti-cancer drug development.
  • To advocate for the development of selective FAK inhibitors.

Main Methods:

  • Review of existing literature on FAK's role in cell signaling and cancer.
  • Analysis of FAK's biochemical and functional links to oncogenes.
  • Evaluation of FAK's prevalence and activity in human cancers.

Main Results:

  • FAK is a key regulator of cellular processes vital for cancer progression.
  • FAK is biochemically and functionally linked to oncogenes.
  • Elevated FAK levels and activity are common across many human cancers.

Conclusions:

  • FAK is a critical factor in tumor development, metastasis, and survival.
  • Selective FAK inhibitors should be developed as a targeted anti-cancer therapy.
  • Combining FAK inhibitors with cytotoxic agents presents a promising therapeutic approach.

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...